Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-CHOP + Ibrutinib in Untreated Young High-Risk DLBCL
NCT02670317Phase 2Terminated
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Sep 2016
- Primary completion
- Feb 2017
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab, ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by Fondazione Italiana Linfomi. Started Sep 2016; status: terminated.
02
Drugs
obinutuzumabibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02670317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02670317.